Gilead Sciences: Non-alcoholic Fatty Liver Disease trials

The registry lists 15 Non-alcoholic Fatty Liver Disease studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 14 have results posted.

Phase 1 3Phase 2 10Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT04971785Phase 2Results posted
• Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT03987074Phase 2Results posted
• A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03551522Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT03449446Phase 2Results posted
• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)TerminatedNCT03053063Phase 3Results posted
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisTerminatedNCT03053050Phase 3Results posted
• Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic FunctionCompletedNCT02891408Phase 1Results posted
• Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic SteatohepatitisCompletedNCT02856555Phase 2Results posted
• Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02854605Phase 2Results posted
• Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic FunctionCompletedNCT02808312Phase 1Results posted
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02781584Phase 2Results posted
• Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and PharmacodynamicsCompletedNCT02654002Phase 1Results posted
• Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3CompletedNCT02466516Phase 2Results posted
• Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)TerminatedNCT01672866Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT00740610Phase 2